Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3323-8
Abstract: The combination of carfilzomib, lenalidomide, and dexamethasone (CRd) has induced deep responses in patients with newly diagnosed multiple myeloma. While vascular endothelial growth factor (VEGF) pathway polymorphisms have been associated with clinical outcomes for antiangiogenesis… read more here.
Keywords: related vegf; carfilzomib lenalidomide; response related; response ... See more keywords